223 related articles for article (PubMed ID: 16599026)
21. Efficacy and safety of oral iron chelating agent deferiprone in beta-thalassemia and hemoglobin E-beta thalassemia.
Adhikari D; Roy TB; Biswas A; Chakraborty ML; Bhattacharya B; Maitra TK; Basu AK; Chandra S
Indian Pediatr; 1995 Aug; 32(8):855-61. PubMed ID: 8635827
[TBL] [Abstract][Full Text] [Related]
22. Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial.
Maggio A; Vitrano A; Capra M; Cuccia L; Gagliardotto F; Filosa A; Romeo MA; Magnano C; Caruso V; Argento C; Gerardi C; Campisi S; Violi P; Malizia R; Cianciulli P; Rizzo M; D'Ascola DG; Quota A; Prossomariti L; Fidone C; Rigano P; Pepe A; D'Amico G; Morabito A; Gluud C
Br J Haematol; 2009 Apr; 145(2):245-54. PubMed ID: 19236376
[TBL] [Abstract][Full Text] [Related]
23. Efficacy, compliance and toxicity factors are affecting the rate of normalization of body iron stores in thalassemia patients using the deferiprone and deferoxamine combination therapy.
Kolnagou A; Kleanthous M; Kontoghiorghes GJ
Hemoglobin; 2011; 35(3):186-98. PubMed ID: 21599431
[TBL] [Abstract][Full Text] [Related]
24. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
El-Beshlawy A; Manz C; Naja M; Eltagui M; Tarabishi C; Youssry I; Sobh H; Hamdy M; Sharaf I; Mostafa A; Shaker O; Hoffbrand AV; Taher A
Ann Hematol; 2008 Jul; 87(7):545-50. PubMed ID: 18351337
[TBL] [Abstract][Full Text] [Related]
25. Pattern of iron chelation therapy in Egyptian beta thalassemic patients: Mansoura University Children's Hospital experience.
Abdelrazik N
Hematology; 2007 Dec; 12(6):577-85. PubMed ID: 17852442
[TBL] [Abstract][Full Text] [Related]
26. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
Barman Balfour JA; Foster RH
Drugs; 1999 Sep; 58(3):553-78. PubMed ID: 10493280
[TBL] [Abstract][Full Text] [Related]
27. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.
Farmaki K; Tzoumari I; Pappa C; Chouliaras G; Berdoukas V
Br J Haematol; 2010 Feb; 148(3):466-75. PubMed ID: 19912219
[TBL] [Abstract][Full Text] [Related]
28. Deferiprone: new preparation. Poorly assessed.
Prescrire Int; 2000 Oct; 9(49):131-5. PubMed ID: 11603411
[TBL] [Abstract][Full Text] [Related]
29. Three most common nonsynonymous UGT1A6*2 polymorphisms (Thr181Ala, Arg184Ser and Ser7Ala) and therapeutic response to deferiprone in β-thalassemia major patients.
Dadheech S; Rao AV; Shaheen U; Hussien MD; Jain S; Jyothy A; Munshi A
Gene; 2013 Dec; 531(2):301-5. PubMed ID: 24036429
[TBL] [Abstract][Full Text] [Related]
30. Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy.
Kolnagou A; Kleanthous M; Kontoghiorghes GJ
Eur J Haematol; 2010 Nov; 85(5):430-8. PubMed ID: 20662901
[TBL] [Abstract][Full Text] [Related]
31. Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone.
Kolnagou A; Michaelides Y; Kontos C; Kyriacou K; Kontoghiorghes GJ
Hemoglobin; 2008; 32(1-2):17-28. PubMed ID: 18274979
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and side effects of deferiprone (L1) in thalassemia patients not compliant with desferrioxamine.
Taher A; Chamoun FM; Koussa S; Saad MA; Khoriaty AI; Neeman R; Mourad FH
Acta Haematol; 1999; 101(4):173-7. PubMed ID: 10436297
[TBL] [Abstract][Full Text] [Related]
33. A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major.
Aydinok Y; Ulger Z; Nart D; Terzi A; Cetiner N; Ellis G; Zimmermann A; Manz C
Haematologica; 2007 Dec; 92(12):1599-606. PubMed ID: 18055982
[TBL] [Abstract][Full Text] [Related]
34. Comparative assessment of deferiprone and deferasirox in thalassemia major patients in the first two decades-single centre experience.
Zachariah M; Tony S; Bashir W; Al Rawas A; Wali Y; Pathare A
Pediatr Hematol Oncol; 2013 Mar; 30(2):104-12. PubMed ID: 23363369
[TBL] [Abstract][Full Text] [Related]
35. Maintenance of normal range body iron store levels for up to 4.5 years in thalassemia major patients using deferiprone monotherapy.
Kolnagou A; Kontoghiorghes GJ
Hemoglobin; 2010 Jun; 34(3):204-9. PubMed ID: 20524810
[TBL] [Abstract][Full Text] [Related]
36. Five-year trial of deferiprone chelation therapy in thalassaemia major patients.
Taher A; Aoun E; Sharara AI; Mourad F; Gharzuddine W; Koussa S; Inati A; Dhillon AP; Hoffbrand AV
Acta Haematol; 2004; 112(4):179-83. PubMed ID: 15564727
[TBL] [Abstract][Full Text] [Related]
37. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies.
Maggio A; Vitrano A; Capra M; Cuccia L; Gagliardotto F; Filosa A; Magnano C; Rizzo M; Caruso V; Gerardi C; Argento C; Campisi S; Cantella F; Commendatore F; D'Ascola DG; Fidone C; Ciancio A; Galati MC; Giuffrida G; Cingari R; Giugno G; Lombardo T; Prossomariti L; Malizia R; Meo A; Roccamo G; Romeo MA; Violi P; Cianciulli P; Rigano P
Blood Cells Mol Dis; 2009; 42(3):247-51. PubMed ID: 19233692
[TBL] [Abstract][Full Text] [Related]
38. Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia.
Tsironi M; Assimakopoulos G; Polonofi K; Rigaki K; Aessopos A
Hemoglobin; 2008; 32(1-2):29-34. PubMed ID: 18274980
[TBL] [Abstract][Full Text] [Related]
39. Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial.
Agarwal MB; Gupte SS; Viswanathan C; Vasandani D; Ramanathan J; Desai N; Puniyani RR; Chhablani AT
Br J Haematol; 1992 Oct; 82(2):460-6. PubMed ID: 1419829
[TBL] [Abstract][Full Text] [Related]
40. Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1.
al-Refaie FN; Wickens DG; Wonke B; Kontoghiorghes GJ; Hoffbrand AV
Br J Haematol; 1992 Oct; 82(2):431-6. PubMed ID: 1419825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
